Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study

Diabetes Obes Metab. 2024 Nov;26(11):5479-5482. doi: 10.1111/dom.15876. Epub 2024 Aug 20.

Authors

Lotte Rasmussen¹, Jacob Harbo Andersen¹, Øystein Karlstad², Diego Hernan Giunta³, Marie Linder³, Kari Furu², Anton Pottegård¹

Affiliations

¹ Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
² Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
³ Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

PMID: 39164856
DOI: 10.1111/dom.15876

No abstract available

Keywords: antidiabetic drug; database research; liraglutide; pharmaco‐epidemiology; semaglutide.

Publication types

Letter

MeSH terms

Adult
Aged
Denmark / epidemiology
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Drug Utilization / statistics & numerical data
Female
Glucagon-Like Peptides* / therapeutic use
Humans
Hypoglycemic Agents* / therapeutic use
Male
Middle Aged
Registries*
Scandinavian and Nordic Countries / epidemiology
Semaglutide

Substances

Glucagon-Like Peptides
Hypoglycemic Agents
Semaglutide